heptad
repeat
spike
protein
sarscov
highli
conserv
region
form
critic
bundl
fusion
step
viru
entri
attract
target
entri
inhibitor
studi
report
minim
peptid
block
fusion
sarscov
ic
find
support
structur
predict
deep
groov
trimer
target
fusion
inhibitor
suggest
potenti
lead
peptid
futur
drug
develop
moreov
combin
peptid
mutat
version
show
synergist
inhibit
ic
combin
index
suggest
common
strategi
achiev
promis
inhibit
peptid
class
envelop
virus
sever
acut
respiratori
syndrom
sar
lifethreaten
diseas
spread
countri
caus
sar
coronaviru
sarscov
drosten
et
al
ksiazek
et
al
peiri
et
al
despit
end
epidem
concern
regard
possibl
resurg
remain
sinc
specif
effect
antisarscov
drug
avail
identif
potenti
target
develop
antivir
agent
critic
effect
treatment
control
diseas
cinatl
et
al
yeung
et
al
among
differ
step
life
cycl
sarscov
viral
entri
attract
target
moor
dom
entri
envelop
rna
virus
involv
fusion
plasma
membran
viral
membran
contain
surfac
envelop
glycoprotein
transmembran
fusion
protein
base
structur
function
similar
fusion
protein
group
two
class
class
class
ii
eckert
kim
kielian
rey
weissenhorn
et
al
class
envelop
virus
influenza
viru
human
immunodefici
viru
type
ebola
viru
measl
viru
murin
hepat
viru
mhv
util
similar
wellstudi
mechan
fusion
interact
two
highli
conserv
heptad
repeat
n
ctermini
respect
fusion
protein
result
format
bundl
structur
fusion
viral
plasma
membran
eckert
kim
weissenhorn
et
al
presum
bind
expos
prehairpin
intermedi
sever
peptid
report
effect
entri
inhibitor
includ
ebola
viru
mhv
develop
drug
enfuvirtid
bosch
et
al
jiang
et
al
kilbi
et
al
watanab
et
al
wild
et
al
recent
combin
peptid
fusion
protein
report
show
synergist
inhibit
potenti
therapeut
implic
gustchina
et
al
spike
protein
sarscov
contain
two
subunit
class
fusion
protein
fig
cinatl
et
al
yeung
et
al
bind
subunit
receptor
angiotensin
convert
enzym
sarscov
enter
cell
either
endosom
pathway
follow
fusion
subunit
contain
two
heptad
repeat
amino
acid
sequenc
peptid
shown
ss
signal
sequenc
tm
transmembran
domain
cy
cytoplasm
tail
number
amino
acid
residu
indic
b
amino
acid
sequenc
peptid
deriv
design
base
residu
e
g
posit
interact
peptid
shown
helic
wheel
represent
three
three
helic
bundl
shown
endosom
membran
direct
fusion
cell
membran
presenc
proteas
li
et
al
simmon
et
al
ujik
et
al
sever
peptid
subunit
report
inhibitori
effect
ic
less
bosch
et
al
liu
et
al
ni
et
al
ujik
et
al
yuan
et
al
zhu
et
al
tabl
howev
larger
length
plausibl
synergist
inhibit
fusion
sarscov
investig
explor
possibl
minim
length
inhibitori
peptid
first
examin
one
smallest
core
structur
protein
resolv
xray
crystallographi
consist
three
three
helic
region
design
shorten
peptid
base
first
report
inhibitori
peptid
overlap
larg
sequenc
design
truncat
version
nterminu
cterminu
end
shown
fig
cell
fusion
inhibit
assay
modifi
previous
describ
report
genebas
sarscov
cell
fusion
assay
xiao
et
al
huentelman
et
al
vrc
plasmid
contain
gene
sarscov
human
codon
usag
design
h
studi
construct
total
rna
extract
cell
qiagen
rneasi
mini
kit
qiagen
valencia
ca
subject
rt
use
random
primer
follow
pcr
use
primer
pair
cccgctc
digest
product
noti
xhoi
clone
respect
site
invitrogen
carlsbad
ca
construct
confirm
sequenc
junction
insert
primer
hela
cell
transfect
g
h
cell
use
lipofectamin
invitrogen
carsblad
ca
infect
recombin
vaccinia
viru
express
multipl
infect
moi
h
posttransfect
hela
cell
transfect
g
cell
infect
recombin
vaccinia
viru
express
polymeras
moi
adsorpt
c
h
replac
fresh
medium
cell
incub
c
overnight
wash
pb
trypsin
wash
pb
twice
resuspend
dmem
contain
fc
cell
cell
well
ad
duplic
preincub
without
differ
concentr
peptid
l
per
well
c
min
cocultur
c
h
cell
lysat
tabl
summari
inhibitori
peptid
deriv
protein
sarscov
measur
activ
use
galctostart
kit
appli
biosystem
bedford
percentag
fusion
ratio
activ
presenc
peptid
absenc
peptid
shown
fig
b
cocultur
hela
cell
express
protein
cell
express
polymeras
cell
result
syncytia
format
rise
activ
rlu
contrast
differ
control
cell
cell
without
transfect
andor
infect
low
signal
demonstr
specif
cell
fusion
assay
initi
test
peptid
high
concentr
reveal
truncat
peptid
inhibitori
effect
fig
inhibitori
activ
test
lower
concentr
similar
doserespons
curv
shown
fig
compar
ic
ic
suggest
truncat
residu
cterminu
still
good
inhibitori
activ
fig
contrast
truncat
cterminu
nterminu
respect
mild
inhibitori
effect
fig
find
suggest
peptid
minim
inhibitori
peptid
region
region
doserespons
curv
also
found
ic
sinc
ic
fold
higher
shorten
fig
instead
design
anoth
peptid
base
predict
interact
residu
e
g
posit
posit
respect
bundl
structur
fig
residu
e
g
posit
replac
e
g
posit
respect
obtain
peptid
similar
ic
fig
next
examin
whether
combin
synergist
effect
compar
doserespons
curv
alon
shift
curv
left
found
combin
fig
ic
plu
molar
ratio
lower
either
alon
ic
also
lower
plu
molar
ratio
data
shown
dose
reduct
indic
molar
ratio
respect
chou
talalay
combin
index
suggest
moder
synerg
chou
studi
report
well
combin
effici
block
fusion
sarscov
inhibitori
effect
peptid
unlik
due
cytotox
sinc
examin
peptid
previous
describ
mtt
assay
reveal
discern
cytotox
hela
cell
highest
concentr
test
data
shown
lai
et
al
differ
peptid
sever
class
envelop
virus
report
entri
inhibitor
bosch
et
al
jiang
et
al
kilbi
et
al
watanab
et
al
wild
et
al
peptid
knowledg
smallest
inhibitori
peptid
class
envelop
virus
examin
biophys
properti
interact
peptid
circulardichro
cd
spectra
analyz
spectropolarimet
model
jasco
inc
japan
rang
nm
c
bandwidth
nm
resolut
nm
respons
time
scan
speed
nmmin
spectrum
averag
scan
peptid
ident
condit
analyz
program
jasco
inc
japan
mix
combin
plu
molar
ratio
variou
concentr
data
mean
standard
error
duplic
well
one
repres
experi
three
shown
equimolar
concentr
complex
show
cd
spectrum
doubl
minima
clear
neg
peak
nm
small
neg
peak
nm
fig
similar
complex
fig
suggest
interact
form
conform
contrast
mix
equimolar
concentr
reveal
cd
spectra
predict
two
peptid
togeth
without
interact
fig
simpl
conveni
cell
fusion
inhibit
assay
use
screen
identifi
entri
inhibitor
sarscov
requir
trypsin
treatment
assay
suggest
mimic
entri
cell
surfac
direct
fusion
viral
cell
membran
simmon
et
al
ujik
et
al
use
similar
assay
huentelman
et
al
recent
report
novel
inhibitor
n
aziridineethanamin
fusion
inhibitor
sarscov
huentelman
et
al
examin
inhibitori
effect
peptid
identifi
cell
fusion
inhibit
assay
sarscov
carri
previous
describ
sarscov
infect
assay
three
peptid
facil
hsueh
et
al
hsueh
et
al
briefli
cell
cell
well
prepar
infect
tcid
sarscov
strain
preincub
without
differ
concentr
peptid
quadric
c
h
incub
c
h
cytopath
effect
observ
light
microscop
ic
determin
welko
obrien
shown
tabl
ic
respect
verifi
inhibitori
effect
sarscov
xray
crystallograph
studi
fusion
core
structur
protein
shown
nterminu
residu
cterminu
residu
beyond
form
two
extend
conform
center
residu
pack
rel
deep
groov
residu
trimer
highli
conserv
predict
potenti
target
fusion
inhibitor
duquerroy
et
al
supekar
et
al
xu
et
al
consist
strong
inhibitori
activ
retain
peptid
ctermin
truncat
residu
beyond
residu
fig
moreov
inhibitori
effect
complet
lost
peptid
ntermin
truncat
ctermin
truncat
suggest
extend
region
nterminu
import
cterminu
tabl
summar
differ
inhibitori
peptid
sarscov
previou
studi
bosch
et
al
liu
et
al
ni
et
al
ujik
et
al
yuan
et
al
zhu
et
al
peptid
ic
rang
nm
depend
locat
length
also
type
peptid
synthet
bacteriaexpress
assay
use
use
assay
inhibitori
activ
total
lost
ad
residu
nterminu
ic
synthet
nm
lower
bacteriaexpress
nm
zhu
et
al
use
differ
assay
ic
determin
infect
assay
higher
pseudotyp
report
viru
assay
moreov
ic
studi
slightli
higher
ic
nm
peptid
similar
length
locat
lower
anoth
studi
ni
et
al
zhu
et
al
studi
use
assay
differ
peptid
warrant
reconcil
discrep
nontheless
inhibitori
peptid
report
thu
far
cover
common
region
defin
residu
correspond
central
helix
supekar
et
al
xu
et
al
tabl
similarli
inhibitori
peptid
cover
region
residu
correspond
deep
groov
find
support
predict
deep
groov
interact
central
helix
import
target
fusion
inhibitor
duquerroy
et
al
supekar
et
al
regard
minim
inhibitori
peptid
cover
central
helix
part
ntermin
extend
region
could
potenti
lead
peptid
futur
drug
develop
compar
inhibitori
effect
peptid
mhv
ebola
viru
sarscov
studi
peptid
weaker
peptid
wild
et
al
watanab
et
al
bosch
et
al
bosch
et
al
liu
et
al
zhu
et
al
use
strategi
employ
design
novel
peptid
mean
ic
interestingli
combin
show
synergist
inhibit
mean
ic
case
mechan
synergist
inhibit
homologu
n
ccg
mutat
peptid
mut
e
g
attribut
differ
target
two
inhibitor
former
interact
latter
interact
inner
core
intact
residu
posit
mutat
residu
e
g
posit
bewley
et
al
gustchina
et
al
conceiv
similar
scenario
may
occur
sarscov
account
synergist
inhibit
though
exact
mechan
remain
investig
nonetheless
find
synergist
inhibit
peptid
mutat
peptid
second
observ
suggest
common
strategi
achiev
good
inhibit
class
envelop
virus
especi
situat
fight
emerg
lifethreaten
infecti
diseas
